{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Hong Kong Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/hk/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/hk/healthcare/feed.json", "description": "Latest Healthcare company headlines from Hong Kong, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:5cf1004518ce6b3bbdcb8e9ebf5c3d63d9dd31e7a7d41bb8185bba7b158fbcab", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPVWpFWTNVWVkwdGd1bWhtaDRZN0ZNNmJVbkR6NzVtcmRLX3dlemo3TUxKcUJERE1SZ3p4azRMekVtSkp5UzBkWWE5V0NkZEFWTzQ5aDBHYVZua3ZidEpfZkdENUdtNFRIdGp0WGg0SDR2U05LeVVjU25EbGlwUHB5Y3hHdGZ1b19mb2xIQ2JmLWdCeGE3Nm1sU1pyZUlZMHp1U2xlSUFOc2t2T050WG9TV3R4NWppbDhsUTYxUnVvNjVtRGxIZWVyV3Nkc0RiZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPVWpFWTNVWVkwdGd1bWhtaDRZN0ZNNmJVbkR6NzVtcmRLX3dlemo3TUxKcUJERE1SZ3p4azRMekVtSkp5UzBkWWE5V0NkZEFWTzQ5aDBHYVZua3ZidEpfZkdENUdtNFRIdGp0WGg0SDR2U05LeVVjU25EbGlwUHB5Y3hHdGZ1b19mb2xIQ2JmLWdCeGE3Nm1sU1pyZUlZMHp1U2xlSUFOc2t2T050WG9TV3R4NWppbDhsUTYxUnVvNjVtRGxIZWVyV3Nkc0RiZw?oc=5", "title": "Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance", "content_text": "Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance", "date_published": "2026-08-14T15:13:26+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Regulatory and legal", "6609"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6609", "name": "Shanghai HeartCare Medical Technology Corporation Limited", "sentiment_url": "https://sharemaestro.com/sentiment/582ec333-858c-4b2d-a886-a15675e26330/"}]}}, {"id": "source:443d7e6751207dfa39e6bec8a330b61c3cf9171ed7d3c13fbbbdf5c69ba243f2", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQU0N4ZmRqTTNZV3NGaGJwdVMxZGY5YnVwdHJVS0RuM1NuVGRCX3pXcW1zRkpfaUR4RGxSRDFPVTBzZTNXWWpWdWdjWnlxckEwLXlKUHN5bjhEZGlCMm1ib2pQV0J2M1dndUd5bFBPNzVVN2xDd3BZZkJkYjVrMnUxaVJEazRhY2ZaRERsUDd4OFFiZ2Mwek13Yk9DT3BLTFJHbUJaUWpIc3ZuYWxEOTluY2ZSZ0pjeXhw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQU0N4ZmRqTTNZV3NGaGJwdVMxZGY5YnVwdHJVS0RuM1NuVGRCX3pXcW1zRkpfaUR4RGxSRDFPVTBzZTNXWWpWdWdjWnlxckEwLXlKUHN5bjhEZGlCMm1ib2pQV0J2M1dndUd5bFBPNzVVN2xDd3BZZkJkYjVrMnUxaVJEazRhY2ZaRERsUDd4OFFiZ2Mwek13Yk9DT3BLTFJHbUJaUWpIc3ZuYWxEOTluY2ZSZ0pjeXhw?oc=5", "title": "Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing", "content_text": "Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing", "date_published": "2026-08-14T15:13:26+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "6609"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6609", "name": "Shanghai HeartCare Medical Technology Corporation Limited", "sentiment_url": "https://sharemaestro.com/sentiment/582ec333-858c-4b2d-a886-a15675e26330/"}]}}, {"id": "source:84ca3a76cb9843f673d0d97cfcc8f26d3c8f80629cdb05dee7100b47fdcd37b8", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWEhuSWlYaktSSENtcUV0ZWtOd01NVXBxMkhMalFnWVdQWmpnb1hSbEZzVkYtY2JzOGduYlVOMGFtWHNjMU9YT0hWNWJFMjZLd3JDdERHSFVnbjFiWVRzWktnX1B2dkM0SGZDMko2QWdvYlpnOF9LNWJqdWYzUElGa0lXLXJiOVJfVFJUWXpFZ0dWLXlXZDJvblN3VG85Vi1iNUM3aS1jZUQ0SmZNOG5PU3UwMDZPTlFoQndKeU05VFBvQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQWEhuSWlYaktSSENtcUV0ZWtOd01NVXBxMkhMalFnWVdQWmpnb1hSbEZzVkYtY2JzOGduYlVOMGFtWHNjMU9YT0hWNWJFMjZLd3JDdERHSFVnbjFiWVRzWktnX1B2dkM0SGZDMko2QWdvYlpnOF9LNWJqdWYzUElGa0lXLXJiOVJfVFJUWXpFZ0dWLXlXZDJvblN3VG85Vi1iNUM3aS1jZUQ0SmZNOG5PU3UwMDZPTlFoQndKeU05VFBvQQ?oc=5", "title": "New Century Healthcare Flags Bank Account Freeze Linked to Partner Probe", "content_text": "New Century Healthcare Flags Bank Account Freeze Linked to Partner Probe", "date_published": "2026-08-14T13:16:49+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Regulatory and legal", "1518"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1518", "name": "New Century Healthcare Holding Co. Limited", "sentiment_url": "https://sharemaestro.com/sentiment/0b8be9fe-4a28-4c64-9111-4e883ebd78f0/"}]}}, {"id": "source:70abd6ef929e8b3f7db40da9c22f8c3e7f7176b5b68508db68d41fccf5a17f34", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxONW9xamJCU1NUeTFuZGQ4TE5TNlhqbWh5cWxXWHZWUy1LZ0M0MGpYUDFvZllnUU1pdmJmQklFclNDSTVBRVc0VGJSRGxiUjlfcktzRFdDaHQwVnRIVHJfeHNOcW5zLUQzUVRRbHN5ajVIWDlwRnVaMGlBZFFadXRRYmVZcE92WlY5Q3ZjQzJxZ2ZmYTlueG5rd1FXWVkwVVBSZTUyS1lmcWRNWUZWN2M5UFZJdnM0STNtVEhQVkt1QUs3WmR6WjNLN0RtLWFueExlemdWZElxMWtVYnJqR1pv?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxONW9xamJCU1NUeTFuZGQ4TE5TNlhqbWh5cWxXWHZWUy1LZ0M0MGpYUDFvZllnUU1pdmJmQklFclNDSTVBRVc0VGJSRGxiUjlfcktzRFdDaHQwVnRIVHJfeHNOcW5zLUQzUVRRbHN5ajVIWDlwRnVaMGlBZFFadXRRYmVZcE92WlY5Q3ZjQzJxZ2ZmYTlueG5rd1FXWVkwVVBSZTUyS1lmcWRNWUZWN2M5UFZJdnM0STNtVEhQVkt1QUs3WmR6WjNLN0RtLWFueExlemdWZElxMWtVYnJqR1pv?oc=5", "title": "Wenzhou Kangning Hospital Shifts Supervisor Xu Yongjiu to Proposed Non-Executive Director Role", "content_text": "Wenzhou Kangning Hospital Shifts Supervisor Xu Yongjiu to Proposed Non-Executive Director Role", "date_published": "2026-08-14T12:50:45+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "2120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2120", "name": "Wenzhou Kangning Hospital Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/32a7b659-51a2-48a0-a09f-59faf82897c4/"}]}}, {"id": "source:e012eaedb5615a28278f7995129963b8432c6e99570641a3c9a6c4a773ea6f8c", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQQzYtbFpHeGppdDk2UXJJVXB2T3Q0SDBiQjhvTkdqMEMtVGNiM2szbzcxempfcnRMblVuUGFnRjVkVG1OSGR6eHNQRUpuWFF3OS1RX2NDalFmaUZzU0ItbGR1SzhFU2lZTk1WVlBmM1RaR2RreUZoUUw5ODNFUjZYdHJHQTI0OUcxUzJxNWtPbzJwVGRfT0VPc29jNXd5b3pIQ3QwbGtTMGlxcVZfVjRtel9VdFlpSXd3VjN1c2p3Uy1lNHZJV3c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQQzYtbFpHeGppdDk2UXJJVXB2T3Q0SDBiQjhvTkdqMEMtVGNiM2szbzcxempfcnRMblVuUGFnRjVkVG1OSGR6eHNQRUpuWFF3OS1RX2NDalFmaUZzU0ItbGR1SzhFU2lZTk1WVlBmM1RaR2RreUZoUUw5ODNFUjZYdHJHQTI0OUcxUzJxNWtPbzJwVGRfT0VPc29jNXd5b3pIQ3QwbGtTMGlxcVZfVjRtel9VdFlpSXd3VjN1c2p3Uy1lNHZJV3c?oc=5", "title": "Wenzhou Kangning Moves to Update Articles and Strengthen Elderly Care Focus", "content_text": "Wenzhou Kangning Moves to Update Articles and Strengthen Elderly Care Focus", "date_published": "2026-08-14T12:18:54+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "2120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2120", "name": "Wenzhou Kangning Hospital Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/32a7b659-51a2-48a0-a09f-59faf82897c4/"}]}}, {"id": "source:c51ab33a92d2a2e1f8ff3c3797f4946ad2f0f27bc5eb897f3e0fede987822700", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNMXMzMWY2dGZHZ0VyTHRTNmtTNFREWjUzbWhPVjYwcUZGZnlzN01tZkNVejkzWEdZY3BnOFV5bUhuc2h1dTBQUlhXdGc4aGZudGhKVmh0Wkp0MktiTFd2em9mQ3BpZzk3a09lc1FjTjhmUWpJRU9SM2FoZ0plaVdmMFVaLVFuMzNhUjJCQUFRTS0xN0NYTXJtSXl3UlVTbVJwc2VyVjZkRkhLekliMkVFVGJrcG40aGZMQUh3aFI1dWNUSmZfd3lRN0NjNTNjeGRZbzhsT1gzLVZkWDFmeUtMR3lR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNMXMzMWY2dGZHZ0VyTHRTNmtTNFREWjUzbWhPVjYwcUZGZnlzN01tZkNVejkzWEdZY3BnOFV5bUhuc2h1dTBQUlhXdGc4aGZudGhKVmh0Wkp0MktiTFd2em9mQ3BpZzk3a09lc1FjTjhmUWpJRU9SM2FoZ0plaVdmMFVaLVFuMzNhUjJCQUFRTS0xN0NYTXJtSXl3UlVTbVJwc2VyVjZkRkhLekliMkVFVGJrcG40aGZMQUh3aFI1dWNUSmZfd3lRN0NjNTNjeGRZbzhsT1gzLVZkWDFmeUtMR3lR?oc=5", "title": "MicroPort CardioFlow Medtech Sets Board Meeting to Approve Interim Results and Consider Dividend", "content_text": "MicroPort CardioFlow Medtech Sets Board Meeting to Approve Interim Results and Consider Dividend", "date_published": "2026-08-14T11:16:23+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2160"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2160", "name": "MicroPort CardioFlow Medtech Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/69ad4dc5-6bf4-407f-b357-4dfee2c202fd/"}]}}, {"id": "source:109bf8cd960bcc80206544dcd10e231a7adfc1149da587fb7e880cbf89160cf1", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbDNGLVc1ZTRYZlRDbVAta2Q5MFJCRXBwSXlqWGJwVkNXZHRfX3g2TEhqa25wVGVtWFdPbU5KbUVMMU8wcUhFOVM5cWEzU1ltRzN3OUdlUXBzbE5yV08xVDhNSmItOXdudDBTcXkyalVKSkVucDBNenYyVGxVa1dVNXN5ZDFFMnNrLXhGaTNmZU1icXpnMW1JVkJqSFZUMHNXOE9wVVFLQUNoN1lSaEt2Qm0yd3JJZTRycjM4dUU2c3VyNWU1U2hVNnBTR3F6d1h3NFE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbDNGLVc1ZTRYZlRDbVAta2Q5MFJCRXBwSXlqWGJwVkNXZHRfX3g2TEhqa25wVGVtWFdPbU5KbUVMMU8wcUhFOVM5cWEzU1ltRzN3OUdlUXBzbE5yV08xVDhNSmItOXdudDBTcXkyalVKSkVucDBNenYyVGxVa1dVNXN5ZDFFMnNrLXhGaTNmZU1icXpnMW1JVkJqSFZUMHNXOE9wVVFLQUNoN1lSaEt2Qm0yd3JJZTRycjM4dUU2c3VyNWU1U2hVNnBTR3F6d1h3NFE?oc=5", "title": "Hony Media Group Flags Sharply Reduced Loss on Segment Turnaround and Asset Disposal", "content_text": "Hony Media Group Flags Sharply Reduced Loss on Segment Turnaround and Asset Disposal", "date_published": "2026-08-14T10:54:21+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "0419"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0419", "name": "Hony Media Group", "sentiment_url": "https://sharemaestro.com/sentiment/979964a4-85dc-4230-bbd1-d5f0f9ff80c5/"}]}}, {"id": "source:0eaef42da0d4e28effb0572999a289bca7caadd9f74c6877cdbe43e82a4c4cbd", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPTWtTeDVfZG01bGtwYnAxOFBuM09IOElfaFplRDh0bjF1T2VNRU5qeWhtOHVHa1JteFJ6dHBBRXVzMGFBbkNDeWx5X25DNWxMa3VXNXl6cDlyZ3B6TmFibGlySkZUaXRIa1VfLUpycWtNanZFT2ZoXy1YekRCMzhIUmpGTzVjQkdfY3UwZmZwbGpJcVEzQ29aX3JTN2NoUTMxNWJiX2U1VHZBLWNoc0RpU29nZjNfbG9FeU9hY0RFcDRxeE8zaDk0c05GYUs5VWVVQXp3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPTWtTeDVfZG01bGtwYnAxOFBuM09IOElfaFplRDh0bjF1T2VNRU5qeWhtOHVHa1JteFJ6dHBBRXVzMGFBbkNDeWx5X25DNWxMa3VXNXl6cDlyZ3B6TmFibGlySkZUaXRIa1VfLUpycWtNanZFT2ZoXy1YekRCMzhIUmpGTzVjQkdfY3UwZmZwbGpJcVEzQ29aX3JTN2NoUTMxNWJiX2U1VHZBLWNoc0RpU29nZjNfbG9FeU9hY0RFcDRxeE8zaDk0c05GYUs5VWVVQXp3?oc=5", "title": "Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan", "content_text": "Sihuan Pharmaceutical Sets Board Meeting to Approve Interim Results and Dividend Plan", "date_published": "2026-08-14T09:43:54+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "0460"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0460", "name": "Sihuan Pharmaceutical Holdings Group Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/cc0cd905-09d4-46cf-ad96-96a638ddc895/"}]}}, {"id": "source:c8c8d889e95db493d733e7aa337d7a78593791d912f2897c2602c5bc2fe43eef", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVTk2TExHLWxuRG5hTkZFN0VnYkpWTHZzVDdRSGhZbWZfbW9iaEN1VjBPeGk4NDl5cWhicVNPelRNYjVRS1p6ZG0yS1ZWdVE2MVlKbEQ1eVFDWTdUcXZJS0FnNHJyeF8zSUp3MUdaOFA0WmljUWxzRTVucFE0R1pVS0t2dTdETDRFeVVPRk0zM3Y1MHVNbF9vN3hVb19rRXZncDBVN2JBVmhyNGFrUXRHSmJhMUxfcXlITEU5YVF5Rk1yaGctZmRB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNVTk2TExHLWxuRG5hTkZFN0VnYkpWTHZzVDdRSGhZbWZfbW9iaEN1VjBPeGk4NDl5cWhicVNPelRNYjVRS1p6ZG0yS1ZWdVE2MVlKbEQ1eVFDWTdUcXZJS0FnNHJyeF8zSUp3MUdaOFA0WmljUWxzRTVucFE0R1pVS0t2dTdETDRFeVVPRk0zM3Y1MHVNbF9vN3hVb19rRXZncDBVN2JBVmhyNGFrUXRHSmJhMUxfcXlITEU5YVF5Rk1yaGctZmRB?oc=5", "title": "Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend", "content_text": "Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend", "date_published": "2026-08-14T08:57:44+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1873"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1873", "name": "Viva Biotech Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/3323c5a5-8cfe-42f2-89b4-1624d43065fd/"}]}}, {"id": "source:00536030d7d2d4999cb9c704413e9637a9a741ede0a287ab68d1325a88651bd7", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQX3d4cUw1RWNzTEFtZVJkUnVLWi1KbVY3azZZSGlLS21saU9IcENiMDdSNDlpMVVLTWM3Z3k4OXJIM1UtcF9IUGdObmlERVM5WlVyN29PYm8yV2xCaEhHNkZQcER4RGdxNVZBcFlWamI5TjBMZ0dSd2tvRThlOE9JWnVJM19SVDg5Z0d4NVVNOGhEOGpwdWFDeU1FYnNQOW1BWUlSR3lOUlA1Snd3MGJ4aktHX081VkU4Y25aUlluZVVNdVY2TUZ1R2l1THl5dFJEMkY0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQX3d4cUw1RWNzTEFtZVJkUnVLWi1KbVY3azZZSGlLS21saU9IcENiMDdSNDlpMVVLTWM3Z3k4OXJIM1UtcF9IUGdObmlERVM5WlVyN29PYm8yV2xCaEhHNkZQcER4RGdxNVZBcFlWamI5TjBMZ0dSd2tvRThlOE9JWnVJM19SVDg5Z0d4NVVNOGhEOGpwdWFDeU1FYnNQOW1BWUlSR3lOUlA1Snd3MGJ4aktHX081VkU4Y25aUlluZVVNdVY2TUZ1R2l1THl5dFJEMkY0?oc=5", "title": "Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend", "content_text": "Shanghai Bio-heart Sets Board Meeting to Review Interim Results and Possible Dividend", "date_published": "2026-08-14T08:57:42+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2185"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2185", "name": "Shanghai Bio-heart Biological Technology Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/f78539b8-87ac-49d8-bff1-ada6b1dc8daf/"}]}}, {"id": "source:e5a20bda332e7c09e4ec2358e1cb0e760e9c13215c924e78b5f7a4f6384fa775", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNLW1BQ3RDZ05XZ2VNZk5RR1pKTElETWt2Qkt1azRqZjZyd0E2S1FKb00ybDZEU1pvdmdZQVk3dVJlbzJBYlpGbFNxaWsza2FPWXJ6OWhVbzk1b192X0czcG1QTGxMQ1ZtWGJLcE5YTlJEMFFsM2o3MHMzQjk4dFJLTnZqQ1dfT0Jlb1EzY2pGZ3JnU01fT2JMUWdVeXhHemFsU1ZiWGwyblFLeWpLMFhzUDBXT3EzWklNamZiZzEyeUQ3OXNZTFNYMkJaZTdpRjU4cDBIVUZ5ZmdzdHQ4QTBkcWhfR3pmdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNLW1BQ3RDZ05XZ2VNZk5RR1pKTElETWt2Qkt1azRqZjZyd0E2S1FKb00ybDZEU1pvdmdZQVk3dVJlbzJBYlpGbFNxaWsza2FPWXJ6OWhVbzk1b192X0czcG1QTGxMQ1ZtWGJLcE5YTlJEMFFsM2o3MHMzQjk4dFJLTnZqQ1dfT0Jlb1EzY2pGZ3JnU01fT2JMUWdVeXhHemFsU1ZiWGwyblFLeWpLMFhzUDBXT3EzWklNamZiZzEyeUQ3OXNZTFNYMkJaZTdpRjU4cDBIVUZ5ZmdzdHQ4QTBkcWhfR3pmdw?oc=5", "title": "383,728,970 H Shares of Guangzhou Innogen Pharmaceutical Group Co., Ltd are subject to a Lock-Up Agreement Ending on 14-AUG-2026.", "content_text": "383,728,970 H Shares of Guangzhou Innogen Pharmaceutical Group Co., Ltd are subject to a Lock-Up Agreement Ending on 14-AUG-2026.", "date_published": "2026-08-14T00:37:25+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Market update", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:857368de7c85bc5668f5564ce664a089e02ca083eab9aef981fa3b8a879d1483", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Insider Stock Buying Reaches CN\u00a5264.4m On Shanghai INT Medical Instruments", "content_text": "Insider Stock Buying Reaches CN\u00a5264.4m On Shanghai INT Medical Instruments", "date_published": "2026-08-14T00:08:32+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "1501"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1501", "name": "Shanghai INT Medical Instruments Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/948cb025-bcda-417a-ae97-0da87ea82885/"}]}}, {"id": "source:184e8d8f36543c49df9f4cb4608eb8a7e6e2a886ca8fa2a7ac2dedd154d5da13", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRTlINFR4Q0haSV9CWHdmdjJLdWdDQTgwTHVNVThGSWlqQ0I0M3JZcVNyamhFMnNCdXY2MkhUcEhDckZITFRmMVNFaTljZ3BnMTBZOFVyVlM4aGxLS3UyQ2QxdEdTLWlxVnVmeHZYUUdLQW9iTWtudEdRVGN2cExobzloZFAxTzF1c3pSNHlnV0NtRDBZNTdEMUEwWTNYY1h2cnE4aWYzU3IyWXJPWHFJUWUwTnpDeDdGZG5YeVNPS3RCTXBTSTYycEUydDU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRTlINFR4Q0haSV9CWHdmdjJLdWdDQTgwTHVNVThGSWlqQ0I0M3JZcVNyamhFMnNCdXY2MkhUcEhDckZITFRmMVNFaTljZ3BnMTBZOFVyVlM4aGxLS3UyQ2QxdEdTLWlxVnVmeHZYUUdLQW9iTWtudEdRVGN2cExobzloZFAxTzF1c3pSNHlnV0NtRDBZNTdEMUEwWTNYY1h2cnE4aWYzU3IyWXJPWHFJUWUwTnpDeDdGZG5YeVNPS3RCTXBTSTYycEUydDU?oc=5", "title": "Sisram Medical Sets Final 2025 Dividend and Clarifies 20% Israeli Withholding Tax", "content_text": "Sisram Medical Sets Final 2025 Dividend and Clarifies 20% Israeli Withholding Tax", "date_published": "2026-08-13T10:40:53+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Capital return", "1696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1696", "name": "Sisram Medical Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/d5c0226a-1b84-4ed2-8814-ea65bbf0dd19/"}]}}, {"id": "source:51fedfabdff81994d1ea52440ea3f7c7bb14081663788ee02b3156abfa2ffc05", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQd0d2bnVXV1EyM29DcHdldGFfNkYwVElMNThFYW9aZDBuSi1BYVJKeWVhZFlmdDZOaFZ1M2xBaWFFcG1HRTJPUXZYWHBPOTNtN1ExMGZYUzJpNC1PcXA0anlSNTAxQ3JWZHR1SVRIWERLLTJyX1hhdXhuT3RfdEZ3N1hxM0pIZzh1Yl9PZ2V5WS1CSlhaRjRQYm5TSkMxYnlQdzMyZ0tUX0VzQzNMaU10bnZDbDJFNkp1S0JLci1B?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQd0d2bnVXV1EyM29DcHdldGFfNkYwVElMNThFYW9aZDBuSi1BYVJKeWVhZFlmdDZOaFZ1M2xBaWFFcG1HRTJPUXZYWHBPOTNtN1ExMGZYUzJpNC1PcXA0anlSNTAxQ3JWZHR1SVRIWERLLTJyX1hhdXhuT3RfdEZ3N1hxM0pIZzh1Yl9PZ2V5WS1CSlhaRjRQYm5TSkMxYnlQdzMyZ0tUX0VzQzNMaU10bnZDbDJFNkp1S0JLci1B?oc=5", "title": "Sisram Medical Sets Record Date and Tax Terms for 2025 Final Dividend", "content_text": "Sisram Medical Sets Record Date and Tax Terms for 2025 Final Dividend", "date_published": "2026-08-13T10:40:53+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Capital return", "1696"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1696", "name": "Sisram Medical Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/d5c0226a-1b84-4ed2-8814-ea65bbf0dd19/"}]}}, {"id": "source:dc49b65b676eafee1a948bb4d2c4b365f9b6e15894cdfef853c55eed75bd6764", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSVFjLV83WE9RNFRsTG0yZ2swOTJVWFY1STh2LXB1MzJvdzdFYml5ZS1URnA2UkJncmRZYWtVenNqRGtGT19pUU1Fc2p3UVN3VWZwQUhmcmoyTFZaYUhJcTIxcjhoMmhsbUNhNVF5VzZvSk1ZWm5sTFhOM3NBNmJDbWtOd0hRRV9tQmhfSFdrMlZGX0VpNk1QQUJpNHVrM0dlVXA4MFdvOVNUQ3I5WWM1WWZET29ZYXFzS0R1aVJBcWJhdTJIWjVwamt3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSVFjLV83WE9RNFRsTG0yZ2swOTJVWFY1STh2LXB1MzJvdzdFYml5ZS1URnA2UkJncmRZYWtVenNqRGtGT19pUU1Fc2p3UVN3VWZwQUhmcmoyTFZaYUhJcTIxcjhoMmhsbUNhNVF5VzZvSk1ZWm5sTFhOM3NBNmJDbWtOd0hRRV9tQmhfSFdrMlZGX0VpNk1QQUJpNHVrM0dlVXA4MFdvOVNUQ3I5WWM1WWZET29ZYXFzS0R1aVJBcWJhdTJIWjVwamt3?oc=5", "title": "Modern Dental Group Forecasts Sharp Interim Profit Growth on Overseas Strength", "content_text": "Modern Dental Group Forecasts Sharp Interim Profit Growth on Overseas Strength", "date_published": "2026-08-13T10:22:45+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "3600"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "3600", "name": "Modern Dental Group Limited", "sentiment_url": "https://sharemaestro.com/sentiment/8582d116-df5a-464d-8575-c35c82b0c205/"}]}}, {"id": "source:e215972b6e316f6385e1bbfa8f6c95646b4902322d349ba65d1b348b7339af3c", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVFhza2JkWGRQeVItOHZURWs3dnB1ZmJhVkVQTmR5bXV5TnNQcHR2bjRaTkRwQmpPQ0dXcTNFYVRNV1RxQXd3LUhaYmVvZjRmeTJnUEJ5cTdJVGxRdU9SV0g1ZHVLVXJGMzFfT3JBVDRreG1ZY19seFhsbi1FTm1HUWJMY0N2T2F4aTYzZ3RQQmZobjJOR3psTE5NQi1XSzhBRGtfSU9iMU42N2RETnJTUEsyT2lTODF5ZnRTaTg1azNzakhIN2xVMQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPVFhza2JkWGRQeVItOHZURWs3dnB1ZmJhVkVQTmR5bXV5TnNQcHR2bjRaTkRwQmpPQ0dXcTNFYVRNV1RxQXd3LUhaYmVvZjRmeTJnUEJ5cTdJVGxRdU9SV0g1ZHVLVXJGMzFfT3JBVDRreG1ZY19seFhsbi1FTm1HUWJMY0N2T2F4aTYzZ3RQQmZobjJOR3psTE5NQi1XSzhBRGtfSU9iMU42N2RETnJTUEsyT2lTODF5ZnRTaTg1azNzakhIN2xVMQ?oc=5", "title": "Austar Lifesciences Sets Board Meeting to Review Interim Results and Dividend", "content_text": "Austar Lifesciences Sets Board Meeting to Review Interim Results and Dividend", "date_published": "2026-08-13T10:02:15+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "6118"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6118", "name": "Austar Lifesciences Limited", "sentiment_url": "https://sharemaestro.com/sentiment/d97bb44a-fadc-4881-898d-b31bb8e629da/"}]}}, {"id": "source:e75be98a118b6341c7be1ff2e4d5fa67a22f1fe813f701e9186e7443aaf3839d", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNLTN0RnpWb1hWemFWTGNScFVuaEtNM1hlWEhPRVRtWEZTVDJxWTZ6MDFzd2tLS1hQa2RrYlprTkkxOVRrYmZ1R0FsWlBWR3IxYnhPZU8yTzRfS0J1d29wZ0xQWTVqOVY3S2dHY1haaXcyQlBhZUZnR0dING9TZjNSdE1STEtELTItM1RFbWdkeER6dERRYjZYYXEzcm1qVjE0djFseF95UXB4bVJXcVh4SHdXdGxZTExXMk1YeC1ZTlI0MWFyWnV2dU1XXzkwVkpzYUlvYnVmRzktUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNLTN0RnpWb1hWemFWTGNScFVuaEtNM1hlWEhPRVRtWEZTVDJxWTZ6MDFzd2tLS1hQa2RrYlprTkkxOVRrYmZ1R0FsWlBWR3IxYnhPZU8yTzRfS0J1d29wZ0xQWTVqOVY3S2dHY1haaXcyQlBhZUZnR0dING9TZjNSdE1STEtELTItM1RFbWdkeER6dERRYjZYYXEzcm1qVjE0djFseF95UXB4bVJXcVh4SHdXdGxZTExXMk1YeC1ZTlI0MWFyWnV2dU1XXzkwVkpzYUlvYnVmRzktUQ?oc=5", "title": "Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan", "content_text": "Guangzhou Innogen Schedules Board Meeting to Review 2026 Interim Results and Dividend Plan", "date_published": "2026-08-13T09:34:01+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2591"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2591", "name": "Guangzhou Innogen Pharmaceutical Group Co., Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/b2e7b5de-50d1-40ae-9dba-193877077f7a/"}]}}, {"id": "source:29c2dab877eb22c4121bf2ca67bc631ca1c4bf97f44354af398bd74b3bdb7498", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQd0M0cHJCVXIwd0hMdktPWVBUbnlmaTBPUlZvUE9yeG1sWVptU0wtcFVaUXd6NXBBMHJ6NGFja0lweWg0bDQ3TUlSRHdVTkYwelhqQThpVVBtWGk0cXBRd295Y0RRTE85bURyWmcza2hCWDNiMVNreUYxazdCdU11VTJZbDlRbWc5NlU4bFlBUlozeVRRTHZUdTRJLTFSb0djNFZwMzFaWGVQRlhjaHdlNTZnN0xSY1FQYl95NURyNXJQZDNyUm1wdHRn?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQd0M0cHJCVXIwd0hMdktPWVBUbnlmaTBPUlZvUE9yeG1sWVptU0wtcFVaUXd6NXBBMHJ6NGFja0lweWg0bDQ3TUlSRHdVTkYwelhqQThpVVBtWGk0cXBRd295Y0RRTE85bURyWmcza2hCWDNiMVNreUYxazdCdU11VTJZbDlRbWc5NlU4bFlBUlozeVRRTHZUdTRJLTFSb0djNFZwMzFaWGVQRlhjaHdlNTZnN0xSY1FQYl95NURyNXJQZDNyUm1wdHRn?oc=5", "title": "Beijing Health Sets Board Meeting to Approve 2026 Interim Results and Dividend", "content_text": "Beijing Health Sets Board Meeting to Approve 2026 Interim Results and Dividend", "date_published": "2026-08-13T09:24:01+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2389"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2389", "name": "Beijing Health (Holdings) Limited", "sentiment_url": "https://sharemaestro.com/sentiment/7925fa86-c3ca-422a-9e23-4a441196053f/"}]}}, {"id": "source:3f1f5d49de2384c949e1f6f06a122b3cfdf99649d54f6a4851c9dd50f9ca7167", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPWU1DeExpcS1HX196VE9tMGE2MTY3dENwWE13amZOTWFSZ0pXRUF5UkRXVkJpT3hmdUs3TjJ3U3YyM2prSjN1MFM0bjlwRi05LUo2OG9BUGV1UWVoeFMzYTVNZWtxaTJmYWp1emhaMVFKRmJyS0JNMDNGWkFkVmR1LWgwXzdTMzl1NGtvNXQzUmFLOW85bVBDQVBFS0ozTjBhSE90cVhUTHl0ajdLRTJXUzFMX1QxMG9JeFpoSF9BbjV5cmtkYi1Z?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPWU1DeExpcS1HX196VE9tMGE2MTY3dENwWE13amZOTWFSZ0pXRUF5UkRXVkJpT3hmdUs3TjJ3U3YyM2prSjN1MFM0bjlwRi05LUo2OG9BUGV1UWVoeFMzYTVNZWtxaTJmYWp1emhaMVFKRmJyS0JNMDNGWkFkVmR1LWgwXzdTMzl1NGtvNXQzUmFLOW85bVBDQVBFS0ozTjBhSE90cVhUTHl0ajdLRTJXUzFMX1QxMG9JeFpoSF9BbjV5cmtkYi1Z?oc=5", "title": "Arts Optical Sets Board Meeting to Approve 2026 Interim Results and Dividend", "content_text": "Arts Optical Sets Board Meeting to Approve 2026 Interim Results and Dividend", "date_published": "2026-08-13T09:24:00+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1120", "name": "Arts Optical International Holdings Limited", "sentiment_url": "https://sharemaestro.com/sentiment/e6ffc821-6a5d-428f-a5d7-db1bf86343ab/"}]}}, {"id": "source:5139f1784c8d678476a64d97c2d4a55b427320ddf245a93c604f0e9ff74eaa44", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQa0RiN3Q2ZUVicEhZdlVzckpUUXBnRmJhTVBEYUJMU2pWQ0dlMEp6RFpKenhQTmIybDVPQnMwUWRKc3BlNF9GTkxFeGEtUE1yU2ZBeHFBTXV5OWJIdy1EWk11N1NzdTZrUThhNFhvXzVoR08zSS02WU9IeEFZSWVYRGMzdUJaYXg0RzBFSlhhVHV2QkYxcWhHSzJNa0w4OWVKWlBvSFlUX1hpVDZXNUtoU0lBNkxmUWZ0alM4R2QydmdqakVQVmx1Rw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxQa0RiN3Q2ZUVicEhZdlVzckpUUXBnRmJhTVBEYUJMU2pWQ0dlMEp6RFpKenhQTmIybDVPQnMwUWRKc3BlNF9GTkxFeGEtUE1yU2ZBeHFBTXV5OWJIdy1EWk11N1NzdTZrUThhNFhvXzVoR08zSS02WU9IeEFZSWVYRGMzdUJaYXg0RzBFSlhhVHV2QkYxcWhHSzJNa0w4OWVKWlBvSFlUX1hpVDZXNUtoU0lBNkxmUWZ0alM4R2QydmdqakVQVmx1Rw?oc=5", "title": "Beijing Chunlizhengda Schedules Board Meeting to Approve 2026 Interim Results", "content_text": "Beijing Chunlizhengda Schedules Board Meeting to Approve 2026 Interim Results", "date_published": "2026-08-13T09:03:55+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1858"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1858", "name": "Beijing Chunlizhengda Medical Instruments Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/89afd966-b4c8-44e3-9567-d32733b744d0/"}]}}, {"id": "source:600ad22bd557ff450cdccc0f7657b5942d3c8ba776985e4725e313c0742a8287", "url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "external_url": "https://finance.yahoo.com/healthcare/articles/beone-medicines-ltd-onc-q2-010458606.html", "title": "BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...", "content_text": "This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing 31% growth. TEVIMBRA Global Sales: $229 million, representing 18% growth versus the prior period. Amgen In-Licensed Portfolio Revenue: $157 million, growing 25% year over year. US Revenue: Approximately $899 million, growing 31% year over year. China Revenue: Approximately $500 million, growing 17% year over year. Europe Revenue: Approximately $208 million, growing 37% year over year. Rest of World Revenue: Approximately $73 million, more than doubled year over year. Gross Profit: $1.5 billion with gross margin of just under 90%. Operating Expenses: $1.2 billion, representing 13% growth. Income from Operations: $325 million. Net Income: $237 million, including an approximate $60 million impact from a tax audit settlement. Adjusted Income from Operations: $503 million, representing growth of more than 80% year over year. Adjusted Net Income: $444 million. Adjusted Diluted EPS: $3.84, compared with $2.25 a year ago. Free Cash Flow: $435 million, doubling from the prior year period. 2026 Revenue Guidance: Raised by $300 million to a range of $6.6 billion to $6.8 billion. 2026 GAAP Operating Income Guidance: Raised by $250 million to a range of $1 billion to $1.1 billion. 2026 Non-GAAP Operating Income Guidance: $1.7 billion to $1.8 billion. Warning! GuruFocus has detected 5 Warning Sign with ONC. Is ONC fairly valued? Test your thesis with our free DCF calculator. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BeOne Medicines Ltd (NASDAQ:ONC) delivered a strong Q2 2026 with total revenues of $1.7 billion, up 30% year-over-year, and GAAP EPS of $2.05, up 144%. BRUKINSA continues to outperform, with global revenues exceeding $1.2 billion (31% growth) and the highest level of sustained new patient starts since launch. The company raised its 2026 revenue guidance by $300 million to $6.6-$6.8 billion and operating income guidance by $250 million to $1.0-$1.1 billion. The Phase 3 MANGROVE study showed BRUKINSA plus rituximab as the first chemo-free regimen for frontline mantle cell lymphoma, with a hazard ratio of 0.57 versus standard of care. The pipeline is advancing rapidly, with five solid tumor programs achieving proof of concept and moving to pivotal trials, including CDK4, B7-H4 ADC, and GPC3 x 4-1BB. Real-world data from over 10,500 Medicare patients showed BRUKINSA significantly reduced risk of death by 24% vs acalabrutinib and 36% vs ibrutinib. The company achieved FDA approval for BEQALZI, the first BCL-2 inhibitor for mantle cell lymphoma, expanding its hematology franchise. Free cash flow doubled year-over-year to $435 million, demonstrating strong cash generation and financial health. Story Continues Negative Points The CELESTIAL-301 study of zanubrutinib plus sonrotoclax did not meet the uMRD superiority endpoint versus venetoclax plus obinutuzumab, raising questions about the regimen's comparative efficacy. The company remains unblinded to the hazard ratio data from CELESTIAL-301, creating uncertainty about the PFS endpoint. Competition from fixed-duration regimens like acalabrutinib plus venetoclax (AV) is emerging, though the company downplays its near-term impact. The company faces potential biosimilar competition for XGEVA from its Amgen in-licensed portfolio, which could impact future revenue. Operating expenses are expected to grow at a similar year-over-year rate in 2027, indicating continued high investment levels that may pressure margins. The company's narrative on BRUKINSA's safety and efficacy is challenged by cross-trial comparisons, which may not fully account for differences in patient populations and stud", "date_published": "2026-08-13T01:04:58+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "6160"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6160", "name": "BeOne Medicines AG", "sentiment_url": "https://sharemaestro.com/sentiment/14ab05a4-a757-4bae-a95d-8990f66c2cff/"}]}}, {"id": "source:cf93f5e329d66a84a3c495ef6dd056e52da8a55f347604660ea6988bf21bae94", "url": "https://finance.yahoo.com/technology/ai/articles/xtalpi-holdings-limited-announce-2026-001700280.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/xtalpi-holdings-limited-announce-2026-001700280.html", "title": "XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026", "content_text": "SHENZHEN, China, Aug. 12, 2026 /PRNewswire/ -- XtalPi Holdings Limited (\"XtalPi\", or the \"Company\") (HKEX: 2228), an innovative research platform company powered by artificial intelligence (AI) and robotics, announced that it will report its interim results for the six months ended June 30, 2026 on Wednesday, August 19, 2026, after the Hong Kong market closes. The Company will hold a conference call in Chinese with English simultaneous interpretation at 7:00 PM Hong Kong/Beijing Time on August 19, 2026 (7:00 AM U.S. Eastern Time on the same day). Details for the conference call are as follows: For Chinese original audio channel: Online Registration Link: https://s.comein.cn/rq17nc1c Alternatively, participants may access the conference call by dialing the following numbers: Mainland China: +86-4001510269 International: +86-1021377168 Hong Kong, China: +852-51089680 Taiwan, China: +886-277083288 United States: +1-2087016888 Password: 372185 The replay of the conference call will be available on the Company's investor relations website at https://ir.xtalpi.com/en/investor-relations. For English simultaneous interpretation channel: Online Registration Link: https://s.comein.cn/95i8s29a About XtalPi XtalPi Holdings Limited (\"XtalPi,\" HKEX: 2228) was founded in 2015 by physicists from the Massachusetts Institute of Technology (MIT). The company is a technology platform focused on quantum physics-based and AI-driven innovation in drug and materials discovery. By integrating quantum physics, artificial intelligence, cloud computing, and large-scale automation, XtalPi provides research and development solutions and services to global pharmaceutical, materials science, consumer products, energy, and advanced chemicals industries. XtalPi leverages AI Agents, proprietary modeling, and advanced robotics to drive rapid scientific discovery by creating autonomous paradigm to solve the most challenging molecular discovery problems. XtalPi's team currently spans Shenzhen, Shanghai, and Beijing in China, Boston in the United States and Liverpool in the United Kingdom. Investor Relations Contact: In China: XtalPi Holdings Limited Investor Relations Email: ir@xtalpi.com Piacente Financial Communications Tel: +86-10-6508-0677 Email: XtalPi@thepiacentegroup.com In the United States: Piacente Financial Communications Brandi Piacente Tel: +1-212-481-2050 Email: XtalPi@thepiacentegroup.comCision View original content to download multimedia:https://www.prnewswire.com/news-releases/xtalpi-holdings-limited-to-announce-2026-interim-results-on-august-19-2026-302850261.html View Comments", "date_published": "2026-08-13T00:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "2228"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2228", "name": "XtalPi Holdings Limited", "sentiment_url": "https://sharemaestro.com/sentiment/54faf369-20f8-487a-966f-04620b99b8d8/"}]}}, {"id": "source:2b89a6c256b10059dd50a2c3552aea4cb75cb48d535895085ee95232921aad1e", "url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ivonescimab-combination-chemotherapy-approved-china-132200149.html", "title": "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer", "content_text": "Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Statistically Significant Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in NSCLC or Any Tumor Type MIAMI, August 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). This marks the third NMPA-approved indication for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024. The latest NMPA approval is based on the positive results of the landmark HARMONi-6 trial, a single region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. HARMONi-6 evaluates ivonescimab in combination with platinum-based chemotherapy compared to tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC irrespective of PD-L1 expression. Overall survival (OS) data from the Phase III HARMONi-6 trial were recently presented in the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. HARMONi-6 demonstrated statistically significant and clinically meaningful superiority in both progression-free survival (PFS) and OS. Ivonescimab continued to demonstrate an acceptable and manageable safety profile in the HARMONi-6 study, which was consistent with previous Phase III studies of ivonescimab plus chemotherapy. \"Today's approval in China marks another extraordinary milestone for ivonescimab and reinforces the strength of the clinical evidence generated to date. HARMONi-6 is the first known Phase III study in NSCLC \u2014 or any tumor type \u2014 to demonstrate a statistically significant and clinically meaningful overall survival benefit over an anti-PD-(L)1 antibody plus chemotherapy regimen in a head-to-head setting,\" said Bob Duggan, Chairman and Co-CEO of Summit. Story Continues \"For Summit, the HARMONi-6 results further strengthen our conviction in ivonescimab's potential to advance beyond today's immunotherapy standards and redefine what patients and physicians can expect from first-line cancer treatment,\" said Dr. Maky Zanganeh, President and Co-CEO of Summit. \"We congratulate our partner Akeso on this important approval and remain focused on accelerating the global development of ivonescimab for patients in our licensed territories.\" \"The NMPA approval of ivonescimab in China in combination with chemotherapy for first-line advanced squamous NSCLC represents a landmark achievement for patients, physicians and the field of oncology. Based on the HARMONi-6 trial, ivonescimab has now demonstrated both progression-free survival and overall survival superiority versus a PD-1 inhibitor plus chemotherapy regimen, establishing a new benchmark in one of the most widely treated settings in cancer care,\" said Dr. Michelle Xia, Chairwoman and Chief Executive Officer of Akeso. \"This third approval for an ivonescimab-containing regimen in China reflects the strength of Akeso's innovation platform, the dedication of our clinical investigators and patients, and the transformative potential of ivonescimab as a next-generation immuno-oncology therapy. Together with Summit, we are committed to bringing the full potential of ivonescimab to patients worldwide.\" In major markets globally, first-line therap", "date_published": "2026-08-12T13:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9926"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9926", "name": "Akeso, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/cfc96b07-c8a4-4446-a224-5b867f724c6a/"}]}}, {"id": "source:ea2b4625a71c3ecf3a801f5cc8b870db88443f52c8875115fac6b586a3885a84", "url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNS3QwYnEyODI2MFJ1Y0dwVTFCb19FQy1JY1JlTzhaN3BjZUhIT0FrYk5tTTAyMmtQb3Azb0lpWXJpOVpkTkJQcWNnWG96TjF0TVR2ZUF4REFSZE5kaHU1M1kwR1A1MENIdVJyczVkN0I1bWx1c3NPVGdyc0k0MUZrSGJidkJ3Z1RmSmlXck5CVDNBRS00d0YxZVNYSklFVTRjLUJlbWJiaHRPV3FkZUp6NGROZGpnWWtEWjdEYXBFWEsxc3BDWTVMTlAxZmZDMlZlNmZ3bVRjWmpJT3lvTS1Rel8zUEppekVQVzNvYnZqSTdDZHpDTVBMSHJQU25tNllpaE02Sk82YnhKUzZNczVDZg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikAJBVV95cUxNS3QwYnEyODI2MFJ1Y0dwVTFCb19FQy1JY1JlTzhaN3BjZUhIT0FrYk5tTTAyMmtQb3Azb0lpWXJpOVpkTkJQcWNnWG96TjF0TVR2ZUF4REFSZE5kaHU1M1kwR1A1MENIdVJyczVkN0I1bWx1c3NPVGdyc0k0MUZrSGJidkJ3Z1RmSmlXck5CVDNBRS00d0YxZVNYSklFVTRjLUJlbWJiaHRPV3FkZUp6NGROZGpnWWtEWjdEYXBFWEsxc3BDWTVMTlAxZmZDMlZlNmZ3bVRjWmpJT3lvTS1Rel8zUEppekVQVzNvYnZqSTdDZHpDTVBMSHJQU25tNllpaE02Sk82YnhKUzZNczVDZg?oc=5", "title": "Hony Media Officially Expands into Robotics Platform Operation Business Establishes Joint Venture AIROBO (HK) to Deepen AI Application Scenarios", "content_text": "Hony Media Officially Expands into Robotics Platform Operation Business Establishes Joint Venture AIROBO (HK) to Deepen AI Application Scenarios", "date_published": "2026-08-12T12:02:13+00:00", "authors": [{"name": "DagangNews"}], "tags": ["Market update", "0419"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0419", "name": "Hony Media Group", "sentiment_url": "https://sharemaestro.com/sentiment/979964a4-85dc-4230-bbd1-d5f0f9ff80c5/"}]}}, {"id": "source:2e54bfbb0bdfb373193bb3d5c2a43197d2a4da131c24d9a77bff45bd6d4aeb1d", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNakVoM0tYVzBwT0JjVTBDMUVpX1ZxUmpZUjBiYkJwLTdfYkt5MW5vYmxLdkV3cHZjR3M1eE5pZUpzT0JRYkhITUsxTVJ3VHhoekd6enY2cV9QZFhWU3BZNXJKQ2NueHZmQS1QS0loSEN3MURWNzhfUkZEdVljZFVNdklZUkplS0x6TlZidVdWQlBKeGU5TEVSTmpyZDYxcC0xTmt5LUM2c1k5OEh5LW1taXNuRUVQN0t6ZFJhY2xGT1JYZmRYeTI0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNakVoM0tYVzBwT0JjVTBDMUVpX1ZxUmpZUjBiYkJwLTdfYkt5MW5vYmxLdkV3cHZjR3M1eE5pZUpzT0JRYkhITUsxTVJ3VHhoekd6enY2cV9QZFhWU3BZNXJKQ2NueHZmQS1QS0loSEN3MURWNzhfUkZEdVljZFVNdklZUkplS0x6TlZidVdWQlBKeGU5TEVSTmpyZDYxcC0xTmt5LUM2c1k5OEh5LW1taXNuRUVQN0t6ZFJhY2xGT1JYZmRYeTI0?oc=5", "title": "Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results", "content_text": "Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results", "date_published": "2026-08-12T10:13:11+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:72a93b842e4e544bc0e08061b04e638ca9eac2128df13fc46f2ba86745daf29c", "url": "https://finance.yahoo.com/healthcare/articles/beyang-closes-oversubscribed-30-million-093800024.html", "external_url": "https://finance.yahoo.com/healthcare/articles/beyang-closes-oversubscribed-30-million-093800024.html", "title": "Beyang Closes Oversubscribed $30 Million Series A Financing", "content_text": "Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co., Ltd. (\"Beyang\"), an AI-driven innovative drug R&D company dedicated to building a \"DreamWorks\" for innovative drug discovery, today announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Capital and Shanghai Healthcar", "date_published": "2026-08-12T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "0867"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0867", "name": "China Medical System Holdings Limited", "sentiment_url": "https://sharemaestro.com/sentiment/4bf4d06a-3706-42b1-a96d-12a632d079b8/"}]}}, {"id": "source:b88136857428843f540fd8d59198881420efec62628fbcc369ed4415761f1f2f", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQbERIR0pDY3dkeC1BV3Jna0Q2UG1UWE5IaHRTbi16VDZ3NDZXRElUdGJqZC1hMVE3LXZteVJKNDZxNmcxeUJlUWd1TndVdDh2Sm1Sa1ZSMDBIN0VzMVRnYWY5OHZCeUtkQXNVN1NTbzl5X3ZuQzdhX0RfTTNYeUlSTVYxMGRJTktSdEdmcGUtcHdZZWlUMEZvSl81X1hyY0p2ZFJpTGJCc0V1clFBV1pCSzZpSEN1RnJCeVhfUFAxQTV3U2ZKVUZEdXNJaTR0Qm5BM0JB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQbERIR0pDY3dkeC1BV3Jna0Q2UG1UWE5IaHRTbi16VDZ3NDZXRElUdGJqZC1hMVE3LXZteVJKNDZxNmcxeUJlUWd1TndVdDh2Sm1Sa1ZSMDBIN0VzMVRnYWY5OHZCeUtkQXNVN1NTbzl5X3ZuQzdhX0RfTTNYeUlSTVYxMGRJTktSdEdmcGUtcHdZZWlUMEZvSl81X1hyY0p2ZFJpTGJCc0V1clFBV1pCSzZpSEN1RnJCeVhfUFAxQTV3U2ZKVUZEdXNJaTR0Qm5BM0JB?oc=5", "title": "Hygeia Healthcare Sets Board Meeting to Approve Interim Results and Consider Dividend", "content_text": "Hygeia Healthcare Sets Board Meeting to Approve Interim Results and Consider Dividend", "date_published": "2026-08-12T09:21:02+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "6078"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6078", "name": "Hygeia Healthcare Holdings Co., Limited", "sentiment_url": "https://sharemaestro.com/sentiment/61ff4d80-b32d-4f09-b417-9204b7419583/"}]}}, {"id": "source:a63806340dc120ff07ba66031a16b807a4191216645b92641b8eb7282abd074f", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNVzVIc0xXZ1E5ZkxOMVA2UXd0Y0xSMm5ZYW9HSFlrUHNEWEtsV2NEc0Y4cGNZN1hDUDR2SUJCZV8wd2I3Z2s4UE5sMURPcXFhNk8yQUVBVm9BZERSNmtNMlU3TnloOTFteERKVUxsRXBGR1N5X2E2RnRid0tOMmJSaWVIc2xpYTVjWDJFY1F1dnV6UzFQQjRaY0E4SThVRUtGZmVhTDNCVVU1T1B1NDNUSGRROFJjYm1zcmgtTTJzR3FiUkV1aFlPN1dDUHJKSmxGTE1obWxDdHdqUnM?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNVzVIc0xXZ1E5ZkxOMVA2UXd0Y0xSMm5ZYW9HSFlrUHNEWEtsV2NEc0Y4cGNZN1hDUDR2SUJCZV8wd2I3Z2s4UE5sMURPcXFhNk8yQUVBVm9BZERSNmtNMlU3TnloOTFteERKVUxsRXBGR1N5X2E2RnRid0tOMmJSaWVIc2xpYTVjWDJFY1F1dnV6UzFQQjRaY0E4SThVRUtGZmVhTDNCVVU1T1B1NDNUSGRROFJjYm1zcmgtTTJzR3FiUkV1aFlPN1dDUHJKSmxGTE1obWxDdHdqUnM?oc=5", "title": "Shanghai Kindly Medical Sets Board Meeting to Approve Interim Results and Consider Dividend", "content_text": "Shanghai Kindly Medical Sets Board Meeting to Approve Interim Results and Consider Dividend", "date_published": "2026-08-12T09:21:01+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1501"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1501", "name": "Shanghai INT Medical Instruments Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/948cb025-bcda-417a-ae97-0da87ea82885/"}]}}, {"id": "source:93aecd2ccc691e58f32b6b65cd508f3d920dfbf83854bd51ed346583796d49f2", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPbnZSMGlzOEVtSlZTSWNPcmJ4ZHhEdTEyeDc1cHowRHJxbFo3WGdsSExqNEdZOGs2bWgyOUNPUG11czRISFNpYS1fQWJRUXQwNENsMlBYcXd3TU9qWGlzWEZrQnV1Qi1tXzNyYUViQ2YzalBxcW8yLWJoRE1xa0hYMUtLUDZDcnd0UkJFbXJSVnozM3RJaklkTnh5UW5mMnFPYzV0RUlPbldHS2NuWV9RSmZJUzM2UQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPbnZSMGlzOEVtSlZTSWNPcmJ4ZHhEdTEyeDc1cHowRHJxbFo3WGdsSExqNEdZOGs2bWgyOUNPUG11czRISFNpYS1fQWJRUXQwNENsMlBYcXd3TU9qWGlzWEZrQnV1Qi1tXzNyYUViQ2YzalBxcW8yLWJoRE1xa0hYMUtLUDZDcnd0UkJFbXJSVnozM3RJaklkTnh5UW5mMnFPYzV0RUlPbldHS2NuWV9RSmZJUzM2UQ?oc=5", "title": "Hony Media Group Launches Robotics Platform Venture With AIROBO", "content_text": "Hony Media Group Launches Robotics Platform Venture With AIROBO", "date_published": "2026-08-12T08:44:53+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "0419"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0419", "name": "Hony Media Group", "sentiment_url": "https://sharemaestro.com/sentiment/979964a4-85dc-4230-bbd1-d5f0f9ff80c5/"}]}}, {"id": "source:75888f862fb99d1fc168057a6c9e61e2eacc5651a5ffc663765ed1e846246f77", "url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "external_url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-081959814.html", "title": "Align Technology Prevails in China Patent Infringement Action", "content_text": "Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China issued a judgment in its favor, in a patent infringement action against Angelalign Technology's operating subsidiaries in China.The company provides an orthodontic treatment system Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-12T08:19:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "6699"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "6699", "name": "Angelalign Technology Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/91e86d71-8251-404e-a95c-514570dc2995/"}]}}, {"id": "source:25c6c21d925fc29deb867a45ff01a76f20251a3b9eef44c35ae8aa00f4114e45", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right", "content_text": "Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right", "date_published": "2026-08-12T07:57:18+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "1672"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1672", "name": "Ascletis Pharma Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/c3d1ab5c-d74a-49c7-a7f9-380f2167dfd4/"}]}}, {"id": "source:62c2b790a504d8ab741a3bfe66a712bd019051a2be167b5862c1efdcc1ff53a7", "url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-004700024.html", "external_url": "https://finance.yahoo.com/healthcare/articles/align-technology-prevails-china-patent-004700024.html", "title": "Align Technology Prevails in China Patent Infringement Action Against Angelalign", "content_text": "SAN JOSE, Calif. & TEMPE, Ariz., August 12, 2026--(BUSINESS WIRE)--Align Technology, Inc. (\"Align\") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign\u00ae System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China (\"Angel\") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align's patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products manufactured and sold using the accused technology also infringe Align's patent. Angel may appeal the judgment to the Supreme People's Court. The deadline for filing an appeal has not yet expired. The court ordered Angel to cease using the patented technology and to stop manufacturing and selling the infringing products in China and awarded Align RMB 10 million in damages. While the ruling remains subject to appeal, Align believes the decision further reinforces the strength of its intellectual property portfolio and ongoing commitment to protecting its innovations globally. The ruling follows other recent developments in Align's patent-enforcement actions against Angel. In February 2026, the Unified Patent Court (\"UPC\") issued a preliminary injunction requiring Angel to cease infringement of Align's patented ClinCheck\u00ae Live Update technology, a decision that was subsequently upheld on appeal. In July 2026, the U.S. International Trade Commission (\"ITC\") conducted an evidentiary hearing concerning five patents asserted by Align against Angel. Align expects that the ITC will make its initial determination regarding the merits of Align's claims in November 2026. Align also continues to pursue additional patent infringement actions against Angel affiliates in China and Europe. \"Align has made significant long-term investments in innovation and in the Chinese market,\" said Joe Hogan, president and chief executive officer of Align Technology. \"We respect the role of China's courts in protecting intellectual property rights and are encouraged by this decision. Protecting intellectual property is essential to sustaining that innovation and ensuring continued investment in technologies that benefit doctors and patients. This decision reinforces the value and strength of Align's intellectual property portfolio and the significant investments we have made to develop industry-leading technologies. We remain committed to supporting fair competition, advancing innovation, and protecting our intellectual property rights while competing in the marketplace.\" Story Continues Align's Cutting-Edge Global Operations As a global leader in digital orthodontics and restorative dentistry with nearly 23.5 million Invisalign\u00ae patients treated worldwide, Align continues to transform the orthodontic industry through its global operations, advanced manufacturing capabilities, and doctor-directed treatment planning. Align's operations span the Americas, EMEA, and APAC regions, with clinical treatment planning centers in Costa Rica, Poland, China (Chengdu), Spain, France, Germany, and Japan. The company's global aligner manufacturing operations includes world-class facilities in Juarez, Mexico; Wroclaw, Poland; and Ziyang, China; Vienna, Austria; San Jose, CA; and a new aligner manufacturing facility coming online in 2027 in Hyderabad, India; together forming the backbone of the world's largest 3D printing netwo", "date_published": "2026-08-12T00:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "6699"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "6699", "name": "Angelalign Technology Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/91e86d71-8251-404e-a95c-514570dc2995/"}]}}, {"id": "source:882798e25bef90730a68e81ca6a8e112c6c71325df036f797edabdf4d04c1039", "url": "https://finance.yahoo.com/healthcare/articles/belenos-biosciences-announces-positive-topline-151000504.html", "external_url": "https://finance.yahoo.com/healthcare/articles/belenos-biosciences-announces-positive-topline-151000504.html", "title": "Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)", "content_text": "The study met its primary and all secondary endpoints at Week 24 Rapid onset of clinical activity was observed with significant improvements as early as Week 4 Durable clinical activity demonstrated following single-dose administration, supporting 6- month dosing for the treatment of CRSwNP '512 was well tolerated across all dosing groups '512 granted Breakthrough Therapy Designation in China for CRSwNP Belenos plans to initiate a Phase 3 study in CRSwNP in 1H 2027 SARASOTA, Fla., August 11, 2026--(BUSINESS WIRE)--Belenos Biosciences, Inc. (\"Belenos\"), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced that '512 met its primary and all secondary endpoints in a double-blind, placebo-controlled Phase 2 clinical study in adults with inadequately controlled CRSwNP (NCT06930612). '512 is known as BEL512 ex-China and CM512 in Greater China. The study was conducted in China by Belenos' partner, Keymed Biosciences, and enrolled 120 patients with CRSwNP with a Nasal Polyp Score of \u22655, with at least 2 polyps per nostril and a Nasal Congestion Score of 2-3 at baseline. Patients were randomized to receive either 300 mg '512 every 12 weeks, 300 mg '512 every 24 weeks, 600 mg '512 every 24 weeks, or placebo via subcutaneous injection on top of daily intranasal corticosteroid treatment (mometasone furoate nasal spray [MFNS 200 \u00b5g QD]). Treatment lasted 24 weeks, followed by a 12-week safety follow-up. The primary endpoint was change from baseline at week 24 (W24) in Nasal Polyp Score (NPS). Additional endpoints evaluated throughout the study were: Nasal Congestion Score (NCS) Loss of Smell (LoS) Score Total Symptom Score (TSS) Sinus CT Lund-Mackay (LMK) score Sinonasal Outcome Test-22 (SNOT-22) The study met its primary and secondary endpoints with statistically significant improvements in the '512 treatment groups vs placebo at W24. Improvements were achieved by W4 and durable effects were observed throughout the treatment and follow-up periods. '512 was well tolerated across all dosing groups with overall treatment-emergent adverse events (TEAEs) rates similar to placebo, no severe TEAEs, no discontinuations in treatment groups, no serious adverse events (SAEs), and minimal anti-drug antibodies (ADA). Based on the results of this study, '512 was recently included by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in its Breakthrough Therapy program for the treatment of CRSwNP. Story Continues \"These results provide important clinical validation for simultaneously targeting TSLP and IL-13 in treating CRSwNP,\" said Donnie McGrath, M.D., CEO of Belenos Biosciences. \"The magnitude, speed of onset and durability of improvement across objective measures of nasal polyp disease and the symptoms that matter most to patients, in conjunction with infrequent dosing indicate that BEL512 may offer patients an attractive treatment option. These findings further strengthen our conviction in BEL512 as a potentially best-in-class therapy across multiple respiratory and inflammatory diseases. We congratulate our partners at Keymed Biosciences on a well-executed study.\" Keymed is rapidly moving to initiate a Phase 3 study in CRSwNP in China in the near future and Belenos will be initiating a Phase 3 study ex-China in the first half of 2027. Detailed results are expected to be presented at a scientific meeting and submitted for publication in a peer-reviewed medical journal. \"Patients with CRSwNP experience a significant and profound impact on their quality of life, struggling to breathe through their nose, smell, and sleep normally. A treatment that works quickly and provides lasting benefits for many months after a single injection would substantially improve both the quality of life and treatment experience for my patients,\" said Dr. Stella Lee, M.D., Associate Professor of Otolaryngology\u2013Head and Neck Surgery at Harvard Medica", "date_published": "2026-08-11T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "2162"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2162", "name": "Keymed Biosciences Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/d613420e-7080-43b0-b7e0-435c91da54a9/"}]}}, {"id": "source:e9fcb368f25410a11559bfefc24603c8a86994cce42733af7b58860edc278c20", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNd2tKREppV0w0TVU1VENRU3p2ZENkbTduS0lraVFqUTlBMzBkZmN4TC05bDRKTHIyUGNscVZsb2lJTlBIMUY0S2NRdTRDb1F0TklocFV3Ql85YUZPTkFtSFFDZFRDXy1rY2gxdHhzR2VpeEdHMFpId3JKbEJncXRoSEs0OTFoekp0RVVwemtXWVVKUS1UamV4THZPMHZWRFk5eENvRmJwdi02bndPaWNrTGJkUmVzWFBDd09CSmVnYXN5YkFfRkE0RHlyUl9tUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNd2tKREppV0w0TVU1VENRU3p2ZENkbTduS0lraVFqUTlBMzBkZmN4TC05bDRKTHIyUGNscVZsb2lJTlBIMUY0S2NRdTRDb1F0TklocFV3Ql85YUZPTkFtSFFDZFRDXy1rY2gxdHhzR2VpeEdHMFpId3JKbEJncXRoSEs0OTFoekp0RVVwemtXWVVKUS1UamV4THZPMHZWRFk5eENvRmJwdi02bndPaWNrTGJkUmVzWFBDd09CSmVnYXN5YkFfRkE0RHlyUl9tUQ?oc=5", "title": "MicroPort CardioFlow Signals Revenue Surge as CRM Acquisition Fuels Global Growth", "content_text": "MicroPort CardioFlow Signals Revenue Surge as CRM Acquisition Fuels Global Growth", "date_published": "2026-08-11T14:44:11+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Deals and strategy", "2160"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2160", "name": "MicroPort CardioFlow Medtech Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/69ad4dc5-6bf4-407f-b357-4dfee2c202fd/"}]}}, {"id": "source:33275f9074ac7e5748fea22e844b199e51f47f588264c883ad7264844f760a2d", "url": "https://finance.yahoo.com/markets/world-indices/articles/asian-equities-traded-us-american-144308450.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/asian-equities-traded-us-american-144308450.html", "title": "Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading", "content_text": "Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday morning, declining 0.14% to 3,020.40 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by diagnostic imaging centers company Concord Medical Services (CCM) and Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-11T14:43:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "9688"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9688", "name": "Zai Lab Limited", "sentiment_url": "https://sharemaestro.com/sentiment/6f0d5f29-758a-4179-96ee-db688e92bca8/"}]}}, {"id": "source:c49f91431ffb32b71c95e285ea7da4d9b496ebad05816d9c4f284581fcc36fb7", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMjMyd21zQ3pJOGV5amhzV3EydHZpem1JdEE4RHlNdzRQbTgxNlRGenpwSDR6M0VvQ0J3UTh2anc2bDJRN0RuZ3ExSlFOVllNWXc5X3BjYUFFZldwYTN1SjFBMGZuR0xiUzhsbk1YTEhRM3FZaXY5TmlTeVVHd21MclJMTUIzODFWRnhFN1FiRnJGRjBPLUZuLWlsUW9IMjE3V2NJLTVWamRPOGUzSy1YSWhYQmZVc0tzMHpKSW9lNjBaOUZCVEVPem9JeGdvUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMjMyd21zQ3pJOGV5amhzV3EydHZpem1JdEE4RHlNdzRQbTgxNlRGenpwSDR6M0VvQ0J3UTh2anc2bDJRN0RuZ3ExSlFOVllNWXc5X3BjYUFFZldwYTN1SjFBMGZuR0xiUzhsbk1YTEhRM3FZaXY5TmlTeVVHd21MclJMTUIzODFWRnhFN1FiRnJGRjBPLUZuLWlsUW9IMjE3V2NJLTVWamRPOGUzSy1YSWhYQmZVc0tzMHpKSW9lNjBaOUZCVEVPem9JeGdvUQ?oc=5", "title": "Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend", "content_text": "Concord Healthcare Schedules Board Meeting to Review Interim Results and Dividend", "date_published": "2026-08-11T11:19:34+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2453"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2453", "name": "Concord Healthcare Group Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/73137340-5d15-487d-a266-f42a1609561e/"}]}}, {"id": "source:5ebedb9a231e5af7a80e2b075e7c0565b263e66744f019360b458c20d64a9f5b", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMUhzVGtSNTNURzI3MU50OTBOZ3dWTDBPYzR3bGVHTUxqMElHV2l3NFoyWmxyMXRrMWY4eFJUWUJwZ0t4cjN4ZkJ1Q1hmVkVUR3pxX2RMTVIyX2Mta3V4WktsMG5xTjI5NXJCTDlyblE1RmJEUklmNXp4RHJGV01FV1l0aWRlRUlOYUNRQzR2NVVDNUhyMGduR09iUE5FdXZkb3hubmtyTXlTMXl5SjY2dHNPTkxvei1ub0ZCdkpjR1hvbjg4dUFYNlZ1dmdDZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQMUhzVGtSNTNURzI3MU50OTBOZ3dWTDBPYzR3bGVHTUxqMElHV2l3NFoyWmxyMXRrMWY4eFJUWUJwZ0t4cjN4ZkJ1Q1hmVkVUR3pxX2RMTVIyX2Mta3V4WktsMG5xTjI5NXJCTDlyblE1RmJEUklmNXp4RHJGV01FV1l0aWRlRUlOYUNRQzR2NVVDNUhyMGduR09iUE5FdXZkb3hubmtyTXlTMXl5SjY2dHNPTkxvei1ub0ZCdkpjR1hvbjg4dUFYNlZ1dmdDZw?oc=5", "title": "Vincent Medical Sets August Board Meeting to Approve Interim Results and Dividend", "content_text": "Vincent Medical Sets August Board Meeting to Approve Interim Results and Dividend", "date_published": "2026-08-11T08:52:58+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "1612"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1612", "name": "Vincent Medical Holdings Limited", "sentiment_url": "https://sharemaestro.com/sentiment/66b53004-e9b9-42c1-8948-560aa513030e/"}]}}, {"id": "source:7d091992f15cfaed25a4e96c2a1d3ef98eadf42e7fa956b649c30379cee7b2a9", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?", "content_text": "Cutia Therapeutics (HKG:2487): Are Analysts Optimistic?", "date_published": "2026-08-11T05:56:25+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "2487"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2487", "name": "Cutia Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/c16d05c0-7950-490a-b83a-895e50b4f8af/"}]}}, {"id": "source:0cd9c1843f06f17aa80c15fff4adbf3ef2e0998894cc34ff42ea3362306812ce", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdGlNVjc5UjY3SThUTzgyZnpyWTRaSjNxUzlvU0hGTjdjcUFKT0tQdV9ZdDRNYVFUOV9DUGt1UWt4eFZ4eG9FQjJ2RnFnczVjUm94RElGMDJ4M2NxY0szNXhrSWh3THhWQl9zWlBkVWh2YlcwUEZyMW8ySWhKM0lqNDZUSGdBMG82YzBGMUlNZlRkai1ob2lSZWRzX09vZzB6Z2Z4eVZYajZRR2s1NExkd3VTVEh4dV9YbEpvTDRJWW5BMVMway1UZ0xnaThOOWJzRFRyTWVlY2lXamRjUDBnSXVOOGdGdw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNdGlNVjc5UjY3SThUTzgyZnpyWTRaSjNxUzlvU0hGTjdjcUFKT0tQdV9ZdDRNYVFUOV9DUGt1UWt4eFZ4eG9FQjJ2RnFnczVjUm94RElGMDJ4M2NxY0szNXhrSWh3THhWQl9zWlBkVWh2YlcwUEZyMW8ySWhKM0lqNDZUSGdBMG82YzBGMUlNZlRkai1ob2lSZWRzX09vZzB6Z2Z4eVZYajZRR2s1NExkd3VTVEh4dV9YbEpvTDRJWW5BMVMway1UZ0xnaThOOWJzRFRyTWVlY2lXamRjUDBnSXVOOGdGdw?oc=5", "title": "Yidu Tech Unit Wins RMB8.6 Million Hospital IT Infrastructure Contract", "content_text": "Yidu Tech Unit Wins RMB8.6 Million Hospital IT Infrastructure Contract", "date_published": "2026-08-11T04:52:41+00:00", "authors": [{"name": "The Globe and Mail"}], "tags": ["Deals and strategy", "2158"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2158", "name": "Yidu Tech Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/f6335eea-81ef-4e8f-824b-eedaaf27147e/"}]}}, {"id": "source:d645fc3285ff9766f61be0095ce259c47f3070ed9f86d196d00b7082c76ed5ea", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPTzQxYkZIcWNHZFJkT0pUMkwyYXluTUUwQVF3Q01NVlNfMEhXWW8xamIzSVl3a0RwUjBDVkcwQWdJWVB6dnpXalp2ZkRrbW9CenFfWnV4ZHhNMFUzczlvQkdXR2swRlZSMV9Ncnh5T0x5SzM2bzFMZXRGR0pRRlFRWVF0anV1SUEtRzNLYnBjd2hreC1LZHcwSG5EaDJ5Qm9PZzM0U2FPYVNIeXBwcklvQWlELW5rZGtEdDNkNXBsdWRHSWY2aFdNcEZiTS1va00?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxPTzQxYkZIcWNHZFJkT0pUMkwyYXluTUUwQVF3Q01NVlNfMEhXWW8xamIzSVl3a0RwUjBDVkcwQWdJWVB6dnpXalp2ZkRrbW9CenFfWnV4ZHhNMFUzczlvQkdXR2swRlZSMV9Ncnh5T0x5SzM2bzFMZXRGR0pRRlFRWVF0anV1SUEtRzNLYnBjd2hreC1LZHcwSG5EaDJ5Qm9PZzM0U2FPYVNIeXBwcklvQWlELW5rZGtEdDNkNXBsdWRHSWY2aFdNcEZiTS1va00?oc=5", "title": "Hony Media Group Sets August Board Meeting to Approve Interim Results and Dividend", "content_text": "Hony Media Group Sets August Board Meeting to Approve Interim Results and Dividend", "date_published": "2026-08-11T04:16:04+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "0419"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "0419", "name": "Hony Media Group", "sentiment_url": "https://sharemaestro.com/sentiment/979964a4-85dc-4230-bbd1-d5f0f9ff80c5/"}]}}, {"id": "source:cc9a76fb5da4315fc9c49447a1fd0c7a9fa9fec1a6dc822ee382fbd0532aa3dd", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSnJKbTJyN2JudElreHV0dnJXNmFLSU5pS08zUmw5TnVaMUdWNVVoR2RYcnRYbVAyeTJ6VWpnbWRvUnY1bnQ5MHVoclpCT2VRQjJFZFp2NDloTHpCZFRybElPVjg1b2tzaXYyT0VEd0JHOWJIYVRIVS1TSmdETXRNaEFqdlo2R1hpRTVhc3I3ZDhuMHRiMjhJRmpZeS16c1ZiR2EtSG9xQWtiYXZXcEdYYkdR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSnJKbTJyN2JudElreHV0dnJXNmFLSU5pS08zUmw5TnVaMUdWNVVoR2RYcnRYbVAyeTJ6VWpnbWRvUnY1bnQ5MHVoclpCT2VRQjJFZFp2NDloTHpCZFRybElPVjg1b2tzaXYyT0VEd0JHOWJIYVRIVS1TSmdETXRNaEFqdlo2R1hpRTVhc3I3ZDhuMHRiMjhJRmpZeS16c1ZiR2EtSG9xQWtiYXZXcEdYYkdR?oc=5", "title": "Antengene Sets Board Meeting to Approve 2026 Interim Results", "content_text": "Antengene Sets Board Meeting to Approve 2026 Interim Results", "date_published": "2026-08-10T23:10:35+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "6996"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "6996", "name": "Antengene Corporation Limited", "sentiment_url": "https://sharemaestro.com/sentiment/3a953705-10d5-42ca-92f3-2c3c0dcfa50a/"}]}}, {"id": "source:dea49b21be6c4307782f427052bdd84e53110c6f2b17145f1b8ad0a04194d232", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE80QjJEd01GbmZjakExREhjUHpmbzc0YW9kWmV3NzBGcjZrdUQ0Yloybk9UOEViMDFlVU5zYTZiMGdBME5SRFFWQ1pHbjVwbTFYY0xrNVlXOHNUcWFmQVhiZ1RwN1ZGQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE80QjJEd01GbmZjakExREhjUHpmbzc0YW9kWmV3NzBGcjZrdUQ0Yloybk9UOEViMDFlVU5zYTZiMGdBME5SRFFWQ1pHbjVwbTFYY0xrNVlXOHNUcWFmQVhiZ1RwN1ZGQQ?oc=5", "title": "Broncus Holding Corporation (2216.HK) stock price, news, quote and history", "content_text": "Broncus Holding Corporation (2216.HK) stock price, news, quote and history", "date_published": "2026-08-10T16:44:00+00:00", "authors": [{"name": "Market source"}], "tags": ["Market update", "2216"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2216", "name": "Broncus Holding Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e497f688-1cf3-467b-8222-9e69014d3e11/"}]}}, {"id": "source:b37dc3cee317ef5810dbaa12f8db640dec61deec612c65ca02464452bcafcf5f", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQY0V6aUwzcF9lb1BqY3ZVaXlDV1J4RE95ZkMwMTJPQ2JfZmtGc3BUMDlKYkFzWnRjU1NtRURGSmNlRzE5NkpwV2NhVVc1X2d4MlNDa2lvWms3MENiMUtpTjZwRUd3WUJiemVNTERhUEhmai1URDBFTWRFT0VYV3dnLS00R3c3LUpLUkVMbGVfSjZrOFdXc0RKQW4wRlI4d3VieUc1RWtjRloxeUNQLWFWOENqVDRmcUlmS2tNQUxEal9Uc3d3aGpjZXluaHhiWUhLb0JF?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQY0V6aUwzcF9lb1BqY3ZVaXlDV1J4RE95ZkMwMTJPQ2JfZmtGc3BUMDlKYkFzWnRjU1NtRURGSmNlRzE5NkpwV2NhVVc1X2d4MlNDa2lvWms3MENiMUtpTjZwRUd3WUJiemVNTERhUEhmai1URDBFTWRFT0VYV3dnLS00R3c3LUpLUkVMbGVfSjZrOFdXc0RKQW4wRlI4d3VieUc1RWtjRloxeUNQLWFWOENqVDRmcUlmS2tNQUxEal9Uc3d3aGpjZXluaHhiWUhLb0JF?oc=5", "title": "Wenzhou Kangning Hospital Posts Higher Revenue but Lower Profit in First Half of 2026", "content_text": "Wenzhou Kangning Hospital Posts Higher Revenue but Lower Profit in First Half of 2026", "date_published": "2026-08-10T15:14:23+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "2120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2120", "name": "Wenzhou Kangning Hospital Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/32a7b659-51a2-48a0-a09f-59faf82897c4/"}]}}, {"id": "source:71dc19307502dfda43e5f292bc7fca470cf8caa5141b2028dc6a56a197fc3e47", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeXVLNUFzZ0pubFJIdmlYNVJoMTBIelFXMXc1dVd0SnVRTU8zbzNMYnhBUXc4NzFoR2pnU3RBX3N3MVZIbTU5UndUQ21YS2NJWXdoMXdYMlh6eGVRa3M3Q0NReEVNWGMzYk1HLXpUVTFUZnVpTmpva3FVMXFwMzVpU2hHbzhFandBZmdhbUY5NmZVVmQxa2JGVkxWbjlqcERXM3UtZGNma2J6STN3cnlZU3lQcVJfWlV6eE5xUmlraGdoUUg1WTJHazB3d3NlOE0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeXVLNUFzZ0pubFJIdmlYNVJoMTBIelFXMXc1dVd0SnVRTU8zbzNMYnhBUXc4NzFoR2pnU3RBX3N3MVZIbTU5UndUQ21YS2NJWXdoMXdYMlh6eGVRa3M3Q0NReEVNWGMzYk1HLXpUVTFUZnVpTmpva3FVMXFwMzVpU2hHbzhFandBZmdhbUY5NmZVVmQxa2JGVkxWbjlqcERXM3UtZGNma2J6STN3cnlZU3lQcVJfWlV6eE5xUmlraGdoUUg1WTJHazB3d3NlOE0?oc=5", "title": "Wenzhou Kangning Hospital Declares Interim Dividend and Sets Withholding Tax Rules", "content_text": "Wenzhou Kangning Hospital Declares Interim Dividend and Sets Withholding Tax Rules", "date_published": "2026-08-10T15:14:23+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Capital return", "2120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2120", "name": "Wenzhou Kangning Hospital Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/32a7b659-51a2-48a0-a09f-59faf82897c4/"}]}}, {"id": "source:d319f1c786d87fe6693fb870b25c4d9832bf924ac724affe85b1b3e3514c3d14", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNbW9YM2hFNENQMG5YRkdjaW40RVpNS1BNeE51eVJxZ1lBX0U2eUpQazZzLVgxVzZxQkFuUmZwMTlrNFNxcF9aWFBvV2licG95U0JBSkh5Y1pLMEhJVWtqS2hOeGNQMFZBU1VNazVQZXkxaGxNWnZhZUtuUE9jZkQ2cVRrTHpmcHBUVnJtUG1aby03X3BKYm9kYmRPajh6dkR5RFdNR0NmVDRRV1lnTmhwcmRPRXFydmdwM3ljVHIxMWNkU0NEazlUbHRaMnJUamhUcWN4NHpnUWNhYUlVWEdxVA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNbW9YM2hFNENQMG5YRkdjaW40RVpNS1BNeE51eVJxZ1lBX0U2eUpQazZzLVgxVzZxQkFuUmZwMTlrNFNxcF9aWFBvV2licG95U0JBSkh5Y1pLMEhJVWtqS2hOeGNQMFZBU1VNazVQZXkxaGxNWnZhZUtuUE9jZkQ2cVRrTHpmcHBUVnJtUG1aby03X3BKYm9kYmRPajh6dkR5RFdNR0NmVDRRV1lnTmhwcmRPRXFydmdwM3ljVHIxMWNkU0NEazlUbHRaMnJUamhUcWN4NHpnUWNhYUlVWEdxVA?oc=5", "title": "Wenzhou Kangning Hospital Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026", "content_text": "Wenzhou Kangning Hospital Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026", "date_published": "2026-08-10T14:42:00+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Earnings", "2120"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "2120", "name": "Wenzhou Kangning Hospital Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/32a7b659-51a2-48a0-a09f-59faf82897c4/"}]}}, {"id": "source:cd955509205a2e67580935731e7df2fd3863c15869e88be6bf32f1b5f88a760f", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOamw4RHE0bWhiWWZxd3M1elMwR0JhRUROWXlDLUFQRVd3U3pzdUJreHp3TlBGelA5Q2FTUFMxSGhOdjZuRjZpdE96allVSGlFQXo1Sm1sWkQ1SUlrallqZTF6YUNLWVhoZ3RJOGFNSGpXOUN0a19uaEx3ZjJwWlRrSUgwSGRPSDBBWU9QRTMzS0F0V25rbGxmblF4SmdoYVUtZ0hCMGpsMDE1R29LSWxOUzZkeV9aLXA3Mm9YYjU1QmZTOUU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOamw4RHE0bWhiWWZxd3M1elMwR0JhRUROWXlDLUFQRVd3U3pzdUJreHp3TlBGelA5Q2FTUFMxSGhOdjZuRjZpdE96allVSGlFQXo1Sm1sWkQ1SUlrallqZTF6YUNLWVhoZ3RJOGFNSGpXOUN0a19uaEx3ZjJwWlRrSUgwSGRPSDBBWU9QRTMzS0F0V25rbGxmblF4SmdoYVUtZ0hCMGpsMDE1R29LSWxOUzZkeV9aLXA3Mm9YYjU1QmZTOUU?oc=5", "title": "Junshi Biosciences Discloses Reduction in Major Shareholder\u2019s Equity Stake", "content_text": "Junshi Biosciences Discloses Reduction in Major Shareholder\u2019s Equity Stake", "date_published": "2026-08-10T13:43:36+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Deals and strategy", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:648442fce7889ee0acebc3d80ff8efe6df78d8f8f5952a614fd4df1eb0f9c48e", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMW4tT0c2SzhzVGhRd09ZaWk5dzRZbnRpdzlRVENyWEk3M1YzV3h1azhQSWFYTGI3cDJzWm9nVS1EcU5zVXBENlViOVBjQXQ1cW5BZWEweGd6a2VBZjFtdXdsSnNtd3lQMmE5cEljTG5kWXNNNVpWbXV2bENHY3dUQXdwQ1N5TXJtRWd1ZVRVVUZULXpWZ3FjSmRNYnlfVDhqSS1lWnNlOUNSdHBHZFg1cXRZYjJEbGhTREJmeW9DM2pjMTFIRUVtNWFB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNMW4tT0c2SzhzVGhRd09ZaWk5dzRZbnRpdzlRVENyWEk3M1YzV3h1azhQSWFYTGI3cDJzWm9nVS1EcU5zVXBENlViOVBjQXQ1cW5BZWEweGd6a2VBZjFtdXdsSnNtd3lQMmE5cEljTG5kWXNNNVpWbXV2bENHY3dUQXdwQ1N5TXJtRWd1ZVRVVUZULXpWZ3FjSmRNYnlfVDhqSS1lWnNlOUNSdHBHZFg1cXRZYjJEbGhTREJmeW9DM2pjMTFIRUVtNWFB?oc=5", "title": "Shanghai Junshi Biosciences Reports Completion of Shareholder\u2019s Stake Reduction", "content_text": "Shanghai Junshi Biosciences Reports Completion of Shareholder\u2019s Stake Reduction", "date_published": "2026-08-10T13:26:05+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Deals and strategy", "1877"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1877", "name": "Shanghai Junshi Biosciences Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/ae80fec0-b67d-47b2-9bd6-da53342c73f1/"}]}}, {"id": "source:715f4fffa460cb7d0f0a0fe9eea8a88766a1350aded2d1e5b72a0e19250ebc5e", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNTzRhME5Fc0RlQnhuc3Nncm1tNzZ5VFVoeS1KZDh6ZlRvckxNRXJPMUlWTDI0S1RjSkt5WTNpS3h4dVNPNHZWaUZDT1dKNGpDbUxXX2lzQXkxSGJjT0NHTUVHS2tFRWhGaVliaG5ReGlhUTJDZUJZdjh5ZE1fMmtRbDVhNlpqM0dka0l3SjB2dk5HUlZKTnhXTC1LMi1FRHo4bVl4dklUejFlZjg2dTVubzNfRUFWR1cwLWZzYlBjVlRSaWFKN3dDaGFVV09zSklLbkdCV0ItUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNTzRhME5Fc0RlQnhuc3Nncm1tNzZ5VFVoeS1KZDh6ZlRvckxNRXJPMUlWTDI0S1RjSkt5WTNpS3h4dVNPNHZWaUZDT1dKNGpDbUxXX2lzQXkxSGJjT0NHTUVHS2tFRWhGaVliaG5ReGlhUTJDZUJZdjh5ZE1fMmtRbDVhNlpqM0dka0l3SjB2dk5HUlZKTnhXTC1LMi1FRHo4bVl4dklUejFlZjg2dTVubzNfRUFWR1cwLWZzYlBjVlRSaWFKN3dDaGFVV09zSklLbkdCV0ItUQ?oc=5", "title": "Town Health shifts Bermuda registered office while maintaining Hong Kong share registrar", "content_text": "Town Health shifts Bermuda registered office while maintaining Hong Kong share registrar", "date_published": "2026-08-10T09:23:19+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "3886"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "3886", "name": "Town Health International Medical Group Limited", "sentiment_url": "https://sharemaestro.com/sentiment/9cd7e3dc-196d-4e8b-84f8-2c6f0a78a633/"}]}}, {"id": "source:21bb470f5d3545f3a896c90cd3e8a46ffd779765d085ae729503a3192c8e6c06", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxORFJ5WlVwOGViTmNFSXVHTWZWNDdHdGVfcDZrVWRtdnBPbHM0aXpzNDFtQjV2U1Y0TFZ5M2xJYTFXNHdIcFFnSVZMazBLT3h2aU9WNk4yVGprTWZFVkZaWkZseDVlRUMzcnVtOVlwUGhCekNiRnNNWmJlVDBEY0hQYTE3RnZNZHMwMjNxeWhEdzVCVEtLamVHMXdMVWtWV3dsOEJ0YUc2aklmcEtBQ2JDOXNSOE0teGdVVDNUbjFSbklLWEpqWGYwd2htYUxPMHlVajdXYw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxORFJ5WlVwOGViTmNFSXVHTWZWNDdHdGVfcDZrVWRtdnBPbHM0aXpzNDFtQjV2U1Y0TFZ5M2xJYTFXNHdIcFFnSVZMazBLT3h2aU9WNk4yVGprTWZFVkZaWkZseDVlRUMzcnVtOVlwUGhCekNiRnNNWmJlVDBEY0hQYTE3RnZNZHMwMjNxeWhEdzVCVEtLamVHMXdMVWtWV3dsOEJ0YUc2aklmcEtBQ2JDOXNSOE0teGdVVDNUbjFSbklLWEpqWGYwd2htYUxPMHlVajdXYw?oc=5", "title": "Shanghai INT Medical Sets Extraordinary General Meeting and Closes Register of Members", "content_text": "Shanghai INT Medical Sets Extraordinary General Meeting and Closes Register of Members", "date_published": "2026-08-10T09:23:19+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Market update", "1501"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "1501", "name": "Shanghai INT Medical Instruments Co., Ltd.", "sentiment_url": "https://sharemaestro.com/sentiment/948cb025-bcda-417a-ae97-0da87ea82885/"}]}}, {"id": "source:ef80cedfb1e2076cbd324b759a34a40329c7d8766a15c065fdc722965d29ac96", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYXdzTXlvbzdPcDg1WUZ4alZBM2JBZGQ4NFQxZkI2TVdjWHBqZ0hNeExJdmJ2TDI0TWEyMHdxTnhyYjY0ZFFfNnBaZllvbHBXVGY0YWNkaDl3MHlpRTlJQ2RESlpTU2kwc2FGQjVTVzZ0c3RLQ0hlUE5GSTBiVHpMU0pXTTNoSkw5aTdUWjVPV2dIc2pOU2RVSGZvTFdEZ0ZPRmZGRHBrN1J3ODBOekhNQjdJWVk2UkVYVldkaVdzMTZlYlh3bmpjNHMtRVZUWTg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQYXdzTXlvbzdPcDg1WUZ4alZBM2JBZGQ4NFQxZkI2TVdjWHBqZ0hNeExJdmJ2TDI0TWEyMHdxTnhyYjY0ZFFfNnBaZllvbHBXVGY0YWNkaDl3MHlpRTlJQ2RESlpTU2kwc2FGQjVTVzZ0c3RLQ0hlUE5GSTBiVHpMU0pXTTNoSkw5aTdUWjVPV2dIc2pOU2RVSGZvTFdEZ0ZPRmZGRHBrN1J3ODBOekhNQjdJWVk2UkVYVldkaVdzMTZlYlh3bmpjNHMtRVZUWTg?oc=5", "title": "Peijia Medical Sets Board Meeting to Approve Interim Results and Consider Dividend", "content_text": "Peijia Medical Sets Board Meeting to Approve Interim Results and Consider Dividend", "date_published": "2026-08-10T09:19:09+00:00", "authors": [{"name": "TipRanks"}], "tags": ["Earnings", "9996"], "_sharemaestro": {"country": "Hong Kong", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "9996", "name": "Peijia Medical Limited", "sentiment_url": "https://sharemaestro.com/sentiment/be4bedc7-f648-4e2d-b860-74e10641b9de/"}]}}]}